Bellus Health

Investors & Media

Press Releases

Press Releases

9/3/19
BELLUS Health Announces the Launch of a US$60 Million Public Offering of Common Shares in Canada and the United States and the Filing of an Application to List Its Common Shares on Nasdaq
LAVAL, Quebec --(BUSINESS WIRE)--Sep. 3, 2019-- BELLUS Health Inc. (“ BELLUS Health” or the “Company”) (TSX: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated July 26, 2019 (the “Base Prospectus”) in connection
8/15/19
BELLUS Health Announces Share Consolidation
LAVAL, Quebec--( BUSINESS WIRE )--BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it is proceeding with
5/21/19
BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference
- Clinical results conclusively demonstrate that BLU-5937, a highly selective P2X3 antagonist, is a differentiated product candidate that has little to no impact on taste perception - - Clinical Phase 2 study to assess the efficacy, safety and tolerability of BLU-5937 in chronic cough patients is
Displaying 1 - 10 of 15